Quanterix Relocates To New Facility
Lexington, MA – Quanterix Corporation, the leading developer of high definition diagnostic tools based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today that it has moved to a newly renovated facility in Lexington, MA to accommodate the company’s recent growth and to support further expansion as it prepares for product commercialization.
The new Lexington facility has been designed to include state-of-the-art laboratory and manufacturing space to support both assay and instrument development. As Quanterix executes its business plan, it expects to accelerate employee growth and fill a number of roles in product development, manufacturing, marketing, sales, and operations.
“This new space will allow us to expand our capabilities and accelerate product development efforts, while continuing to attract best-in-class professionals,” said Martin Madaus, Ph.D., Chairman and CEO of Quanterix. “Quanterix will launch the first fully automated multiplex platform capable of delivering upon the promise of single molecule sensitivity, making it the next generation technology to displace conventional immunoassay and nucleic acid amplification methods. We remain on track to have an instrument available for life science and clinical researchers by the middle of next year, to be followed by an IVD platform that will be cost effective to run in hospitals and specialty labs.”
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. The company plans to launch the Simoa system in 2013.
Media contact for Quanterix:
Share this page